# Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer

> **NCT01610869** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 117 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01610869
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-01-11
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2019-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610869, "Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01610869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*